Shanghai Kaibao Pharmaceutical - Asset Resilience Ratio
Shanghai Kaibao Pharmaceutical (300039) has an Asset Resilience Ratio of 17.36% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Shanghai Kaibao Pharmaceutical (300039) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Shanghai Kaibao Pharmaceutical's Asset Resilience Ratio has changed over time. See 300039 net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Shanghai Kaibao Pharmaceutical's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Shanghai Kaibao Pharmaceutical (300039) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥860.80 Million | 17.36% |
| Total Liquid Assets | CN¥860.80 Million | 17.36% |
Asset Resilience Insights
- Good Liquidity Position: Shanghai Kaibao Pharmaceutical maintains a healthy 17.36% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Shanghai Kaibao Pharmaceutical Industry Peers by Asset Resilience Ratio
Compare Shanghai Kaibao Pharmaceutical's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Shanghai Kaibao Pharmaceutical (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Shanghai Kaibao Pharmaceutical.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 3.98% | CN¥180.02 Million ≈ $26.34 Million |
CN¥4.52 Billion ≈ $661.19 Million |
+0.71pp |
| 2023-12-31 | 3.28% | CN¥150.01 Million ≈ $21.95 Million |
CN¥4.58 Billion ≈ $670.15 Million |
+0.08pp |
| 2022-12-31 | 3.19% | CN¥136.07 Million ≈ $19.91 Million |
CN¥4.26 Billion ≈ $623.27 Million |
+1.67pp |
| 2021-12-31 | 1.53% | CN¥51.26 Million ≈ $7.50 Million |
CN¥3.36 Billion ≈ $491.06 Million |
-2.46pp |
| 2020-12-31 | 3.98% | CN¥114.65 Million ≈ $16.78 Million |
CN¥2.88 Billion ≈ $421.04 Million |
-13.10pp |
| 2019-12-31 | 17.08% | CN¥485.57 Million ≈ $71.05 Million |
CN¥2.84 Billion ≈ $415.95 Million |
+14.01pp |
| 2018-12-31 | 3.07% | CN¥84.28 Million ≈ $12.33 Million |
CN¥2.75 Billion ≈ $402.03 Million |
-0.79pp |
| 2017-12-31 | 3.86% | CN¥103.38 Million ≈ $15.13 Million |
CN¥2.68 Billion ≈ $392.13 Million |
+2.21pp |
| 2016-12-31 | 1.64% | CN¥41.58 Million ≈ $6.08 Million |
CN¥2.53 Billion ≈ $369.91 Million |
+0.67pp |
| 2015-12-31 | 0.98% | CN¥23.72 Million ≈ $3.47 Million |
CN¥2.43 Billion ≈ $355.10 Million |
-8.00pp |
| 2014-12-31 | 8.97% | CN¥190.00 Million ≈ $27.80 Million |
CN¥2.12 Billion ≈ $309.84 Million |
-- |
About Shanghai Kaibao Pharmaceutical
Shanghai Kaibao Pharmaceutical CO.,Ltd engages in the research, development, production, and sale of modern traditional Chinese medicines primarily in China. The company offers heat-clearing and detoxifying products, such as Tanreqing Injection for wind-heat in the lungs with phlegm-heat obstructing the lungs, early-stage pneumonia, acute bronchitis, acute exacerbations of chronic bronchitis, and… Read more